CA3141134A1 - Thiadiazolyl derivatives as dna polymerase theta inhibitors - Google Patents
Thiadiazolyl derivatives as dna polymerase theta inhibitors Download PDFInfo
- Publication number
- CA3141134A1 CA3141134A1 CA3141134A CA3141134A CA3141134A1 CA 3141134 A1 CA3141134 A1 CA 3141134A1 CA 3141134 A CA3141134 A CA 3141134A CA 3141134 A CA3141134 A CA 3141134A CA 3141134 A1 CA3141134 A1 CA 3141134A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- thiadiazol
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855495P | 2019-05-31 | 2019-05-31 | |
| US62/855,495 | 2019-05-31 | ||
| US202062990239P | 2020-03-16 | 2020-03-16 | |
| US62/990,239 | 2020-03-16 | ||
| PCT/US2020/035165 WO2020243459A1 (en) | 2019-05-31 | 2020-05-29 | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3141134A1 true CA3141134A1 (en) | 2020-12-03 |
Family
ID=72179163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3141134A Pending CA3141134A1 (en) | 2019-05-31 | 2020-05-29 | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12509454B2 (https=) |
| EP (1) | EP3976608B1 (https=) |
| JP (1) | JP7655863B2 (https=) |
| CN (1) | CN114127062A (https=) |
| AU (1) | AU2020282768B2 (https=) |
| BR (1) | BR112021024101A2 (https=) |
| CA (1) | CA3141134A1 (https=) |
| ES (1) | ES2968796T3 (https=) |
| TW (1) | TW202110834A (https=) |
| WO (1) | WO2020243459A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023050007A1 (en) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202237595A (zh) * | 2020-12-02 | 2022-10-01 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物 |
| TW202315618A (zh) * | 2021-06-11 | 2023-04-16 | 美商愛德亞生物科學公司 | 作為DNA聚合酶θ抑制劑之O-聯結噻二唑基化合物 |
| WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
| WO2023067515A1 (en) * | 2021-10-22 | 2023-04-27 | Ideaya Biosciences, Inc. | Thiadiazolyl compounds as dna polymerase theta inhibitors |
| EP4455129A4 (en) * | 2021-12-30 | 2025-05-07 | Shanghai Apeiron Therapeutics Company Limited | Dna polymerase theta inhibitor and use thereof |
| CN118510778A (zh) * | 2022-01-12 | 2024-08-16 | 百济神州有限公司 | 作为DNA聚合酶θ抑制剂的噻唑并吡啶基酰胺衍生物 |
| US20250122221A1 (en) | 2022-01-13 | 2025-04-17 | Nanjing Zaiming Pharmaceutical Co., Ltd. | Six-membered cyclothiazole compound and use thereof |
| TW202332442A (zh) | 2022-01-31 | 2023-08-16 | 瑞士商瑞森製藥公司 | ＰＯＬθ抑制劑 |
| CN118871430A (zh) * | 2022-03-10 | 2024-10-29 | 西藏海思科制药有限公司 | DNA聚合酶 θ 抑制剂及其用途 |
| WO2023202623A1 (zh) * | 2022-04-20 | 2023-10-26 | 南京再明医药有限公司 | Polq抑制剂化合物及其应用 |
| CA3257870A1 (en) * | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | THIADIAZOLYL DERIVATIVES USED AS DNA POLYMERASE THETA INHIBITORS AND THEIR USES |
| WO2023241322A1 (en) * | 2022-06-16 | 2023-12-21 | Danatlas Pharmaceuticals Co., Ltd. | Heterocyclic derivatives, compositions and uses thereof |
| AU2023352129A1 (en) * | 2022-09-29 | 2025-05-01 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use |
| AU2023356904A1 (en) * | 2022-10-03 | 2025-05-22 | Recombination Therapeutics, Llc | Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof |
| CN117946138A (zh) * | 2022-10-28 | 2024-04-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其中间体、制备方法和应用 |
| CN120077028A (zh) * | 2022-11-10 | 2025-05-30 | 北京丹擎医药科技有限公司 | 噻二唑衍生物及其组合物和应用 |
| WO2024099336A1 (en) * | 2022-11-10 | 2024-05-16 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolyl derivatives, compositions and uses thereof |
| JP2025541823A (ja) * | 2022-12-09 | 2025-12-23 | グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー４）、リミテッド | Ｄｎａポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用 |
| WO2024149349A1 (zh) * | 2023-01-14 | 2024-07-18 | 西藏海思科制药有限公司 | 靶向Polθ的化合物及其用途 |
| KR20250153866A (ko) | 2023-03-10 | 2025-10-27 | 브레이크포인트 테라퓨틱스 게엠베하 | Dna 중합효소 세타 억제제 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| WO2024213082A1 (en) * | 2023-04-13 | 2024-10-17 | Danatlas Pharmaceuticals Co., Ltd. | Thiadiazolone derivatives, compositions and uses thereof |
| CN121729418A (zh) * | 2023-05-05 | 2026-03-24 | 北京丹擎医药科技有限公司 | 环状衍生物及其组合物和应用 |
| CN121712768A (zh) * | 2023-05-30 | 2026-03-20 | 宁波新湾科技发展有限公司 | 噻唑基或噻二唑基酰胺衍生物及其用途 |
| CN121399118A (zh) * | 2023-06-02 | 2026-01-23 | 成都微芯药业有限公司 | Polθ抑制剂及其制备方法和用途 |
| WO2025011617A1 (zh) * | 2023-07-12 | 2025-01-16 | 杭州圣域生物医药科技有限公司 | 并环杂芳环类化合物、其中间体、制备方法和应用 |
| WO2025011603A1 (zh) * | 2023-07-12 | 2025-01-16 | 南京再明医药有限公司 | 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途 |
| AU2024295853A1 (en) * | 2023-07-12 | 2026-02-12 | Simcere Zaiming Pharmaceutical Co., Ltd. | Salt of thiazolopyrazine compound or crystal thereof and use thereof |
| CN121772924A (zh) * | 2023-07-12 | 2026-03-31 | 先声再明医药股份有限公司 | Polq抑制剂化合物和抗癌治疗剂或者放射疗法的组合 |
| CN121773109A (zh) * | 2023-07-27 | 2026-03-31 | 北京丹擎医药科技有限公司 | PolQ降解剂及其组合物和应用 |
| WO2025036490A1 (zh) * | 2023-08-17 | 2025-02-20 | 海思科医药集团股份有限公司 | 一种DNA聚合酶θ抑制剂及其用途 |
| KR20260040065A (ko) * | 2023-09-01 | 2026-03-23 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | 바이아릴 고리계 화합물, 이의 중간체, 제조 방법 및 용도 |
| CN117229260B (zh) * | 2023-11-13 | 2024-02-27 | 中国药科大学 | DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途 |
| WO2025110780A1 (en) * | 2023-11-24 | 2025-05-30 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| WO2025119195A1 (en) * | 2023-12-08 | 2025-06-12 | Danatlas Pharmaceuticals Co., Ltd. | Combination of polq inhibitor and anti-cancer therapeutic agent |
| WO2025165092A1 (en) * | 2024-01-30 | 2025-08-07 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| WO2025165094A1 (en) * | 2024-01-30 | 2025-08-07 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer |
| CN120829441A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| CN120829442A (zh) * | 2024-04-24 | 2025-10-24 | 杭州圣域生物医药科技有限公司 | 一种并环含氮化合物及其中间体的制备方法 |
| WO2025223483A1 (zh) * | 2024-04-24 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | 并环含氮化合物、其晶型及其制备方法和用途 |
| CN118515661B (zh) * | 2024-07-22 | 2024-11-15 | 中国药科大学 | 一种靶向降解Polθ的化合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| EP3778600A1 (en) * | 2014-03-20 | 2021-02-17 | The Johns Hopkins University | Compounds which inhibit rna polymerase, compositions including such compounds, and their use |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| USRE50319E1 (en) | 2017-10-16 | 2025-03-04 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
-
2020
- 2020-05-29 AU AU2020282768A patent/AU2020282768B2/en active Active
- 2020-05-29 WO PCT/US2020/035165 patent/WO2020243459A1/en not_active Ceased
- 2020-05-29 CA CA3141134A patent/CA3141134A1/en active Pending
- 2020-05-29 CN CN202080050232.1A patent/CN114127062A/zh active Pending
- 2020-05-29 TW TW109118207A patent/TW202110834A/zh unknown
- 2020-05-29 BR BR112021024101A patent/BR112021024101A2/pt unknown
- 2020-05-29 US US17/615,123 patent/US12509454B2/en active Active
- 2020-05-29 JP JP2021570943A patent/JP7655863B2/ja active Active
- 2020-05-29 ES ES20760608T patent/ES2968796T3/es active Active
- 2020-05-29 EP EP20760608.8A patent/EP3976608B1/en active Active
-
2025
- 2025-10-28 US US19/370,959 patent/US20260049074A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023050007A1 (en) * | 2021-09-29 | 2023-04-06 | Repare Therapeutics Inc. | N-(5-substituted-[(1,3,4-thiadiazolyl) or (thiazolyl)])(substituted)carboxamide compounds and use thereof for inhibiting human polymerase theta |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260049074A1 (en) | 2026-02-19 |
| WO2020243459A1 (en) | 2020-12-03 |
| CN114127062A (zh) | 2022-03-01 |
| US20230078112A1 (en) | 2023-03-16 |
| JP7655863B2 (ja) | 2025-04-02 |
| AU2020282768A1 (en) | 2021-12-23 |
| EP3976608A1 (en) | 2022-04-06 |
| BR112021024101A2 (pt) | 2022-02-08 |
| AU2020282768B2 (en) | 2023-09-14 |
| JP2022535227A (ja) | 2022-08-05 |
| EP3976608B1 (en) | 2023-11-08 |
| ES2968796T3 (es) | 2024-05-14 |
| TW202110834A (zh) | 2021-03-16 |
| EP3976608C0 (en) | 2023-11-08 |
| US12509454B2 (en) | 2025-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12509454B2 (en) | Thiadiazolyl derivatives | |
| US11084798B1 (en) | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | |
| AU2021390194B2 (en) | Substituted thiadiazolyl derivatives as dna polymerase theta inhibitors | |
| AU2019204125B2 (en) | 2-(Morpholin-4-yl)-1,7-naphthyridines | |
| AU2022201352A1 (en) | Pyrazole derivatives as MALT1 inhibitors | |
| US9815846B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| EP3066093B9 (en) | Gsk-3 inhibitors | |
| US9862707B2 (en) | TrkA kinase inhibitors, compositions and methods thereof | |
| US9914736B2 (en) | TrKA kinase inhibitors, compositions and methods thereof | |
| WO2016086200A1 (en) | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors | |
| JP2018520201A (ja) | Ｔｇｆベーター受容体アンタゴニスト | |
| CN120225521A (zh) | Akt1调节剂 | |
| RU2830169C2 (ru) | Производные 2-оксохиназолина как ингибиторы метионин аденозилтрансферазы 2a | |
| CN103748095B (zh) | 二环杂芳族化合物 | |
| US20260125346A1 (en) | Isoquinolinone Derivatives and 4H-Quinolizinone Derivatives and Pharmaceutical Compositions Thereof for the Treatment of Disease | |
| SG11202112914SA (en) | Pyrido-pyrimidin derivatives and pharmaceutical composition, for use in preventing or treating pi3 kinase related diseases, comprising same as active ingredient | |
| TW202448420A (zh) | 用於減弱bhlh轉錄因子之myc原癌基因家族之c-myc或n-myc蛋白質的哺乳類轉譯之化合物、組合物及方法 | |
| NZ748986A (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240527 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250606 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251003 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251204 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251204 |